A Phase II Study of Lonsurf (TAS-102) in Metastatic Platinum and Checkpoint Inhibitor-resistant Bladder Cancer

Bladder Cancer Clinical Trial

Official title:

A Phase II Study of TAS-102 in Metastatic Platinum and Checkpoint Inhibitor-resistant Bladder Cancer

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03762161
• Other study ID #: IIT-2018-TAS-102
• Status: Recruiting
• Phase: Phase 2
• Start date: January 3, 2019
• Est. completion date: January 2024

Study information

• Verified date: March 2022
• Source: University of Kansas Medical Center
• Contact: KUCC Navigation
• Phone: 913-588-3671
• Email: kucc_navigation[@]kumc.edu
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study evaluates the clinical benefit of TAS-102 in participants with metastatic urothelial carcinoma who are resistant to cisplatin or carboplatin front-line and checkpoint inhibitors as second line therapy. All participants will receive TAS-102 in oral form twice per day on Days 1-5 and Days 8-12 of each 28 day cycle.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 22
• Est. completion date: January 2024
• Est. primary completion date: July 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Ability of participant to understand this study, and participant willingness to sign a written informed consent.

• Participants must have histologically or cytologically confirmed locally advanced unresectable or metastatic urinary bladder (urothelial) cancer. Participants with mixed histologies are permitted as long as transitional cell carcinoma is present in the pathological specimen.

• Participants must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension

• Documented progression on or within 12 months of treatment with one previous platinum-containing regimen or ineligible to receive platinum-containing regimen. Neo-adjuvant or adjuvant platinum-based chemotherapy will be deemed to be first-line when participants progressed within 12 months of the last dose

• Documented progression on prior checkpoint inhibitor or ineligible to receive check-point inhibitor

• Adequate performance status, organ, and marrow function.

• Women of child-bearing potential and men with partners of child-bearing potential must agree to practice sexual abstinence, or to use two forms of adequate contraception.

• Men of child-bearing potential must not father a child or donate sperm while on this study and for 6 months after their last study treatment

Exclusion Criteria:

• Patients who have had chemotherapy or radiotherapy within 4 weeks of enrollment/registration.

• Current or anticipated use of other investigational agents while participating in this study.

• Psychiatric illness/social situations that would limit compliance with study requirements.

• Pregnant or breast feeding (if applicable).

• Patients with known brain metastases

• History of allergic reactions attributed to compounds of similar chemical or biologic composition to TAS 102.

• Patients with HIV on anti-retro-viral therapy with thymidine kinase substrates, for example, stavudine, zidovudine, telbivudine.

• Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, or cardiac arrhythmia. Undergoing active treatment for a co-existing malignancy with the exception of adequately treated basal cell carcinoma, squamous cell skin cancer, thyroid cancer or incidental prostate adenocarcinoma detected at radical cystectomy

Related Conditions & MeSH terms

• Bladder Cancer
• Urinary Bladder Neoplasms

Intervention

Drug:
• TAS 102
Participant self-administered orally at 35 milligrams per meter squared (mg/m2) twice daily Days 1-5 and 8-12 of every 28 day cycle

Locations

Country	Name	City	State
United States	University of Kansas Cancer Center - Clinical Research Center	Fairway	Kansas
United States	University of Kansas Cancer Center, Westwood Campus	Kansas City	Kansas

Sponsors (2)

Lead Sponsor	Collaborator
Rahul Parikh	Taiho Oncology, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Clinical benefit rate (complete response+ partial response+ stable disease)	Evaluated per Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1	Up to 6 months
Secondary	Progression-free survival rate (PFS) among participants	Evaluated per Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1	Up to 6 months
Secondary	Overall response rate (ORR) among participants	Evaluated per Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1	Up to 12 months
Secondary	Overall survival rate (OS) among participants	Evaluated per Medical Record	Up to 12 months
Secondary	Overall change in patient-reported quality of life outcomes	Evaluated per Functional Assessment of Cancer Therapy - Bladder (FACT-Bl) version 4 - quality of life (QOL) questionnaire scores; FACT-Bl total score range is 0-156, derived by the sum of the sub-scales. Higher scores indicate better QOL.; FACT-Bl includes five sub-scales: Physical Well-being (PWB), score range of 0-28; Social/Family Well-being (SWB), score range of 0-28; Emotional Well-being (EWB), score range of 0-24; Functional Well-being (FWB), score range of 0-28; Bladder Cancer Subscale (BlCS), score range of 0-48; Note: Negatively stated items are reversed by subtracting the response from "4".	Up to 26 months
Secondary	Proportion of participants with Grade 3 or higher Adverse and Serious Adverse Events	Evaluated per Common Terminology Criteria for Adverse Events (CTCAE) v5.0	Up to 26 months